Explore private companies that have undergone mergers or acquisitions.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Inscripta | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $459.69MM | Series E | 4/5/2021 | $150MM | $1.32B | $8.83 | Fidelity, T. Rowe Price | |||||
| Neurona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $342.29MM | Series F | 4/3/2025 | $101.71MM | $578.63MM | $2.06 | Fidelity, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, Spur Capital Partners | |||||
| Chroma Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $262MM | Series B | 3/1/2023 | $135MM | $450.56MM | $2.60 | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | |||||
| Kareo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $136.5MM | Series H | 10/9/2018 | $10MM | $414.8MM | $6.86 | Undisclosed Investors | |||||
| Metabiota | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $84.22MM | Series B | 3/7/2017 | $8.02MM | $156.11MM | $1.84 | WP Global Partners, In-Q-Tel, SharesPost | |||||
| Arthrosi Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $294.54MM | Series E | 10/8/2025 | $148.1MM | $385.03MM | $6.54 | Prime Eight Capital, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech | |||||
| Auris Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $738.23MM | Series D-1 | 11/28/2018 | $220.42MM | $2.13B | $0.21 | Partner Fund Management, Wellington Management, D1 Capital Partners, Senator Investment Group, Mithril Capital Management, Lux Capital, Viking Global Investors | |||||
| Bluejay Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $242.24MM | Series C-1 | 5/9/2024 | $1.14MM | $371.77MM | $6.53 | Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital | |||||
| Alma | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $441.06MM | Series D | 8/25/2022 | $130MM | $788.56MM | $17.52 | Thoma Bravo, Cigna Ventures, Insight Partners, Optum Ventures, Tusk Venture Partners, Primary Venture Partners, Sound Ventures | |||||
| CareBridge Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $190.85MM | Series C | 6/8/2022 | $140MM | $1.15B | $48.24 | Oak HC/FT, Optum Ventures, CVS Ventures, Anthem, HLM Venture Partners | |||||
| Nurx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $90.87MM | Series C-1 | 8/11/2020 | $13.31MM | $317.71MM | $7.32 | Wittington Ventures, Union Square Ventures, Trustbridge Partners, Kleiner Perkins, Comcast Ventures | |||||
| Paige | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $247.3MM | Series C-1 | 3/2/2023 | $19.5MM | $656.14MM | $25.74 | Undisclosed Investors | |||||
| Scorpion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.02B | Series C-2 | 7/16/2024 | $24.31MM | $821.83MM | $2.54 | Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital | |||||
| Shoreline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $186MM | Series B | 11/2/2021 | $140MM | $527.99MM | $10.07 | Ally Bridge Group, Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, Superstring, BVF Partners, Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, Stork Capital, Wedbush Healthcare Partners | |||||
| Doctor on Demand | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $239.67MM | Series D | 7/8/2020 | $78.74MM | $820.61MM | $28.53 | General Atlantic | |||||
| Nalu | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $331.77MM | Series E | 10/9/2024 | $115.06MM | $382.56MM | $4.85 | Novo Holdings, Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, Aperture Venture Partners, B Capital | |||||
| Sail Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.95B | Series BB Prime | 10/19/2023 | $123.4MM | $2.62B | $28.01 | Undisclosed Investors | |||||
| Proteus Digital Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $397.36MM | Series H | 4/15/2016 | $50MM | $1.64B | $15.80 | Undisclosed Investors | |||||
| RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $795.51MM | Series D | 9/13/2022 | $159.75MM | $599.64MM | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | |||||
| Unchained Labs | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Athelas | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $365.02MM | Series B-2 | 10/3/2023 | $60MM | $969.5MM | $103.96 | Undisclosed Investors | |||||
| Capstan Therapeutics | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $845MM | Series B | 3/20/2024 | $175MM | $525.33MM | $3.37 | RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures | |||||
| Kyruus | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $192.53MM | Series E | 9/15/2022 | $35.1MM | $359.84MM | $23.40 | Undisclosed Investors | |||||
| Mindstrong Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $160.35MM | Series C | 5/21/2020 | $100MM | $703.91MM | $8.01 | General Catalyst, ARCH Venture Partners, Foresite Capital, 8VC, Optum Ventures, What If Ventures | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.